SCHEMBL305109

SCHEMBL305109

O=[N+]([O-])c1cc(Cl)c(Cl)cc1O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
CYP3A4 P08684 1/20 0.55
MAPK1 P28482 4/20 0.52
TSHR P16473 3/20 0.52
GPR35 Q9HC97 5/20 0.52
HPGD P15428 3/20 0.50
TP53 P04637 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HSD17B10 Q99714 3/20 0.48
ALOX15 P16050 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
VCAM1 P19320 2/20 0.46
ALDH5A1 P51649 1/20 0.46
ABAT P80404 1/20 0.46
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA9 Q16790 1/20 0.46
KDM4E B2RXH2 3/20 0.45
MAPT P10636 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11555308 0.89 ALDH1A1 (0.69) ALDH1A1CYP3A4MAPK1TSHRGPR35
SCHEMBL8767757 0.89 ALDH1A1 (0.63) ALDH1A1CYP3A4MAPK1TSHRGPR35
SCHEMBL5642359 0.84 ALDH1A1 (0.63) ALDH1A1CYP3A4MAPK1TSHRGPR35
SCHEMBL6482217 0.84 ALDH1A1 (0.49) ALDH1A1CYP3A4MAPK1TSHRGPR35
SCHEMBL11649965 0.84 ALDH1A1 (0.62) ALDH1A1CYP3A4MAPK1TSHRGPR35
SCHEMBL18302570 0.84 ALDH1A1 (0.49) ALDH1A1CYP3A4MAPK1TSHRGPR35
SCHEMBL305329 0.84 ALDH1A1 (0.49) ALDH1A1CYP3A4MAPK1TSHRGPR35
SCHEMBL309310 0.84 ALDH1A1 (0.49) ALDH1A1CYP3A4MAPK1TSHRGPR35
SCHEMBL31220465 0.84 ALDH1A1 (0.49) ALDH1A1CYP3A4MAPK1TSHRGPR35
SCHEMBL18863834 0.84 ALDH1A1 (0.49) ALDH1A1CYP3A4MAPK1TSHRGPR35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260083721-A1 7-CYANO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF JIANGSU YAHONG MEDITECH CO LTD (CN) 2026-03-26 US disclosed
EP-4702021-A1 COMPOUNDS CAPABLE OF MODULATING GPR65 Pathios Therapeutics Limited (GB) 2026-03-04 EP disclosed
EP-4630412-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP disclosed
EP-4623914-A1 USE OF 8-HYDROXYQUINOLINE DERIVATIVE Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-10-01 EP disclosed
US-RE50527-E1 Covalent inhibitors of KRAS G12C ARAXES PHARMA LLC (US) 2025-08-12 US disclosed
CN-120035438-A Use of 8-hydroxyquinoline derivatives 江苏亚虹医药科技股份有限公司 2025-05-23 CN disclosed
EP-4534530-A1 7-CYANO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-04-09 EP disclosed
WO-2024224064-A1 COMPOUNDS CAPABLE OF MODULATING GPR65 Pathios Therapeutics Limited (GB) 2024-10-31 WO disclosed
CN-118679149-A 7-Cyano-8-hydroxyquinoline derivative, preparation method and medical application thereof 江苏亚虹医药科技股份有限公司 2024-09-20 CN disclosed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed
EP-1173440-B1 TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS UPJOHN CO (US) 2004-09-15 EP disclosed
US-20040138202-A1 Tetracyclic azepinoindole compounds PHARMACIA AND UPJOHN COMPANY 2004-07-15 US disclosed
US-20020198190-A1 Tetracyclic azepinoindole compounds PHARMACIA & UPJOHN COMPANY 2002-12-26 US disclosed
US-6407092-B1 5-HYDROXYTRYPTAMINE MODULATORS AND ANTISEROTONINE AGENTS; TREATING EATING, SEXUAL, SLEEP, NERVOUS SYSTEM, PSYCHOLOGICAL, AND GASTROINTESTINAL DISORDERS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS PHARMACIA & UPJOHN COMPANY 2002-06-18 US disclosed
EP-1173440-A1 TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2002-01-23 EP disclosed
WO-2000064899-A1 TETRACYCLIC AZEPINOINDOLE COMPOUNDS AS 5-HT RECEPTOR LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2000-11-02 WO disclosed
EP-0537592-B1 Process for the preparation of 2-nitro-5-fluoro- respectively -5-chloro-phenol HOECHST AG (DE) 1996-01-17 EP disclosed
EP-0537592-A1 Process for the preparation of 2-nitro-5-fluoro- respectively -5-chloro-phenol HOECHST AKTIENGESELLSCHAFT (DE) 1993-04-21 EP disclosed
US-4180572-A Lipogenesis control by esters of benzoxazinecarboxylic acids SHELL OIL COMPANY (US) 1979-12-25 US disclosed
US-4144235-A ANTIPSYCHOTIC, NEUROLEPTIC AMERICAN CYANAMID COMPANY (US) 1979-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083721-A1 7-CYANO-8-HYDROXYQUINOLINE DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF HCCS, SLC38A7, HRAS ALDH1A1 420/4885CYP3A4 135/4885MAPK1 3171/4885
US-20040138202-A1 Tetracyclic azepinoindole compounds TPH1, AZI2, CYP1A2 ALDH1A1 327/4885CYP3A4 55/4885MAPK1 3137/4885
US-20020198190-A1 Tetracyclic azepinoindole compounds TPH1, AZI2, CYP1A2 ALDH1A1 327/4885CYP3A4 55/4885MAPK1 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.